At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial
In Brief
A clinical study evaluating MRI/ultrasound transperineal prostate biopsy and transrectal ultrasound-guided prostate biopsy for Prostate Cancer and 5 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of detecting clinically significant prostate cancer (csPCa) while decreasing the detection of non-significant PCa.
Study Details
Timeline
Interventions
3-6 targeted biopsy cores from each prostate region of interest
12 systematic biopsy cores